Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Insight Partners | PRODUCT CODE: 1134748

Cover Image

PUBLISHER: The Insight Partners | PRODUCT CODE: 1134748

South & Central America Branded Generics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Therapeutic Application, Distribution Channel, Drug Class, and Formulation Type

PUBLISHED:
PAGES: 166 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3000
PDF (Site License)
USD 4000
PDF (Enterprise License)
USD 5000

Add to Cart

The branded generics market in South & Central America is expected to grow from US$ 24.33 billion in 2022 to US$ 43.28 billion by 2028; it is estimated to grow at a CAGR of 10.1% from 2022 to 2028.

The branded generics market growth in South & Central America is attributed to the aging population, flourishing diagnostics market, and increasing initiatives by major players in the medical industry. Furthermore, the rising prevalence of chronic diseases that demand affordable therapeutic options is expected to provide opportunities to the market in this region during the forecast period. By country, the market in the rest of South & Central America is segmented into Chile, Colombia, Peru, Cuba, Venezuela, and Bolivia. These countries are investing significantly in improving healthcare services, focusing on primary and advanced care. According to data by World Bank, ~12% of the population in Chile was reported to be more than 65 years of age in 2020. With the increasing geriatric population, the prevalence of diabetes, cancer, and cardiovascular diseases is also on the rise, simultaneously driving developments in the pharmaceutical and healthcare industries in the rest of South & Central America. Therefore, the expected increase in the number of healthcare settings in these countries and the rise in the geriatric population are likely to provide significant opportunities for the growth of the branded generics market players in the coming years.

By introducing new features and technologies, vendors in the Europe branded generics market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market at a good CAGR during the forecast period.

outh & Central America Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)

South & Central America Branded Generics Market Segmentation

South & Central America branded generics market is segmented into therapeutic application, distribution channel, drug class, formulation type and country. The therapeutic application segment of the South & Central America branded generics market is segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, and analgesics and anti-inflammatory. In 2022, the others segment held the largest share of the market, by therapeutic application. The South & Central America branded generics market, by distribution channel is hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The retail pharmacies segment is likely to hold the largest share of the market in 2022. The South & Central America branded generics market, by drug class is segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and others. The others segment is likely to hold the largest share of the market in 2022. The South & Central America branded generics market, based on formulation type is segmented into oral, parenteral, topical, and other. In 2022, the oral segment held the largest share of the market, by formulation type. Based on country, the South & Central America branded generics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil held the largest market share in 2022.

Aspen Holdings, AstraZeneca, Bausch Health (Valeant Pharmaceuticals), Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Hetero, Lupin, Mylan N.V., Par Pharmaceuticals, Sandoz International Gmbh, Sanofi, and Teva Pharmaceutical Industries Ltd. are among the leading companies in the branded generics market operating in this region.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South & Central America branded generics market
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America branded generics market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the branded generics market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
Product Code: BMIRE00026057

Table Of Contents

1. Introduction

  • 1.1 Study Scope
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 SAM Branded Generics Market - By Therapeutic Application
    • 1.3.2 SAM Branded Generics Market - By Distribution Channel
    • 1.3.3 SAM Branded Generics Market - By Drug Class
    • 1.3.4 SAM Branded Generics Market - By Formulation Type
    • 1.3.5 SAM Branded Generics Market - By Country

2. Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. SAM Branded Generics Market - Market Landscape

  • 4.1 Overview
  • 4.2 SAM PEST Analysis
  • 4.3 Experts Opinion

5. SAM Branded Generics Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Penetration of Branded Generics
  • 5.2 Market Restraints
    • 5.2.1 Switching Brands, Poorer Clinical Outcomes and Adverse Effects of Generic Medications
  • 5.3 Market Opportunities
    • 5.3.1 Product Differentiation
  • 5.4 Future Trends
    • 5.4.1 Encouraging Utility of Branded Generics by Healthcare Providers and Professionals
  • 5.5 Impact Analysis

6. Branded Generics Market- SAM Analysis

  • 6.1 SAM Branded Generics Market Revenue Forecast and Analysis
  • 6.2 SAM Branded Generics Market, By Country - Forecast and Analysis

7. SAM Branded Generics Market Revenue and Forecast To 2028- by Therapeutic Application

  • 7.1 Overview
  • 7.2 SAM Branded Generics Market Revenue Share, By Therapeutic Application: Market Revenue and Forecast Analysis (US$ Billion)
  • 7.3 Oncology
    • 7.3.1 Overview
    • 7.3.2 Oncology Market Revenue and Forecast to 2028 (US$ Billion)
  • 7.4 Cardiovascular Diseases
    • 7.4.1 Overview
    • 7.4.2 Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)
  • 7.5 Diabetes
    • 7.5.1 Overview
    • 7.5.2 Diabetes Market Revenue and Forecast to 2028 (US$ Billion)
  • 7.6 Neurology
    • 7.6.1 Overview
    • 7.6.2 Neurology Market Revenue and Forecast to 2028 (US$ Billion)
  • 7.7 Gastrointestinal Diseases
    • 7.7.1 Overview
    • 7.7.2 Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)
  • 7.8 Dermatology Diseases
    • 7.8.1 Overview
    • 7.8.2 Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)
  • 7.9 Analgesics and Anti-Inflammatory
    • 7.9.1 Overview
    • 7.9.2 Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)
  • 7.10 Others
    • 7.10.1 Overview
    • 7.10.2 Others Market Revenue and Forecast to 2028 (US$ Billion)

8. SAM Branded Generics Market Analysis and Forecast to 2028 by Distribution Channel

  • 8.1 SAM Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)
  • 8.2 Hospital Pharmacies
    • 8.2.1 Overview
    • 8.2.2 Hospital Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 8.3 Retail Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Retail Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 8.4 Online Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Online Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 8.5 Drug Stores
    • 8.5.1 Overview
    • 8.5.2 Drug Stores: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)

9. SAM Branded Generics Market Analysis and Forecast to 2028 by Drug Class

  • 9.1 SAM Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)
  • 9.2 Alkylating Agents
    • 9.2.1 Overview
    • 9.2.2 Alkylating Agents: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 9.3 Antimetabolites
    • 9.3.1 Overview
    • 9.3.2 Antimetabolites: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 9.4 Hormones
    • 9.4.1 Overview
    • 9.4.2 Hormones: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 9.5 Anti-hypertensive
    • 9.5.1 Overview
    • 9.5.2 Anti-hypertensive: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 9.6 Lipid Lowering Drugs
    • 9.6.1 Overview
    • 9.6.2 Lipid Lowering Drugs: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 9.7 Anti-Depressants
    • 9.7.1 Overview
    • 9.7.2 Anti-Depressants: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 9.8 Anti-psychotics
    • 9.8.1 Overview
    • 9.8.2 Anti-psychotics: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 9.9 Anti-epileptic
    • 9.9.1 Overview
    • 9.9.2 Anti-epileptic: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • 9.10 Others
    • 9.10.1 Overview
    • 9.10.2 Others: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)

10. SAM Branded Generics Market Analysis and Forecast to 2028 - by Formulation Type

  • 10.1 Overview
  • 10.2 SAM Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)
  • 10.3 Oral
    • 10.3.1 Overview
    • 10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Billion)
  • 10.4 Parenteral
    • 10.4.1 Overview
    • 10.4.2 Parenteral Market Revenue and Forecast to 2028 (US$ Billion)
  • 10.5 Topical
    • 10.5.1 Overview
    • 10.5.2 Topical Market Revenue and Forecast to 2028 (US$ Billion)
  • 10.6 Others
    • 10.6.1 Overview
    • 10.6.2 Others Market Revenue and Forecast to 2028 (US$ Billion)

11. SAM Branded Generics Market Revenue and Forecasts to 2028 Country Analysis

  • 11.1 Overview
    • 11.1.1 SAM: Branded Generics Market Revenue and Forecasts to 2028, By Country (%)
      • 11.1.1.1 Argentina Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
        • 11.1.1.1.1 Overview
        • 11.1.1.1.2 Argentina: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
        • 11.1.1.1.3 Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
        • 11.1.1.1.4 Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
        • 11.1.1.1.5 Argentina: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
        • 11.1.1.1.6 Argentina: Branded Generics Market, by Formulation Type- Revenue and Forecast to 2028 (US$ Billion)
      • 11.1.1.2 Brazil: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
        • 11.1.1.2.1 Overview
        • 11.1.1.2.2 Brazil: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
        • 11.1.1.2.3 Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
        • 11.1.1.2.4 Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
        • 11.1.1.2.5 Brazil: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
        • 11.1.1.2.6 Brazil: Branded Generics Market, by Formulation Type- Revenue and Forecast to 2028 (US$ Billion)
      • 11.1.1.3 Rest of South and Central America: Branded Generics Market- Revenue and Forecast to 2028 (USD Billion)
        • 11.1.1.3.1 Overview
        • 11.1.1.3.2 Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
        • 11.1.1.3.3 Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
        • 11.1.1.3.4 Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
        • 11.1.1.3.5 Rest of SAM: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
        • 11.1.1.3.6 Rest of SAM: Branded Generics Market, by Formulation Type- Revenue and Forecast to 2028 (US$ Billion)

12. Branded Generics Market-Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in the Market (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 MYLAN N.V.
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 GlaxoSmithKline plc.
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Bausch Health Companies Inc.
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Lupin
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Sanofi
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 ASTRAZENECA PLC.
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Dr. Reddy's Laboratories
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Par Pharmaceuticals, INC
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Sandoz International GMBH
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Aspen Holdings
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments
  • 13.12 Hetero
    • 13.12.1 Key Facts
    • 13.12.2 Business Description
    • 13.12.3 Products and Services
    • 13.12.4 Financial Overview
    • 13.12.5 SWOT Analysis
    • 13.12.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms
Product Code: BMIRE00026057

List Of Tables

  • Table 1.             Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
  • Table 2.             Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
  • Table 3.             Argentina: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
  • Table 4.             Argentina: Branded Generics Market, by Formulation Type- Revenue and Forecast to 2028 (US$ Billion)
  • Table 5.             Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
  • Table 6.             Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
  • Table 7.             Brazil: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
  • Table 8.             Brazil: Branded Generics Market, by Formulation Type- Revenue and Forecast to 2028 (US$ Billion)
  • Table 9.             Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
  • Table 10.          Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
  • Table 11.          Rest of SAM: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
  • Table 12.          Rest of SAM: Branded Generics Market, by Formulation Type- Revenue and Forecast to 2028 (US$ Billion)
  • Table 13.          Organic Developments Done By Companies
  • Table 14.          Inorganic Developments Done By Companies
  • Table 15.          Glossary of Terms

List Of Figures

  • Figure 1.           SAM Branded Generics Market Segmentation
  • Figure 2.           SAM Branded Generics Market, By Country
  • Figure 3.           SAM Branded Generics Market Overview
  • Figure 4.           Others Segment Held Largest Share of Drug Class Segment in SAM Branded Generics Market
  • Figure 5.           Brazil is Expected to Show Remarkable Growth During the Forecast Period
  • Figure 6.           SAM: PEST Analysis
  • Figure 7.           Experts Opinion
  • Figure 8.           Impact Analysis of Drivers and Restraints on SAM Branded Generics Market
  • Figure 9.           SAM Branded Generics Market - By Country Forecast and Analysis - 2019 - 2028
  • Figure 10.        SAM Branded Generics Market Revenue Share, By Therapeutic Application: Market Analysis and Forecast 2022 and 2028 (%)
  • Figure 11.        SAM Oncology Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 12.        SAM Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 13.        SAM Diabetes Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 14.        SAM Neurology Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 15.        SAM Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 16.        SAM Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 17.        SAM Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 18.        SAM Others Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 19.        SAM Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)
  • Figure 20.        SAM Hospital Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 21.        SAM Retail Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 22.        SAM Online Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 23.        SAM Drug Stores: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 24.        SAM Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)
  • Figure 25.        SAM Alkylating Agents: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 26.        SAM Antimetabolites: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 27.        SAM Hormones: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 28.        SAM Anti-hypertensive: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 29.        SAM Lipid Lowering Drugs: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 30.        SAM Anti-Depressants: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 31.        SAM Anti-psychotics: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 32.        SAM Anti-epileptic: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 33.        SAM Others: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
  • Figure 34.        SAM Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)
  • Figure 35.        SAM Oral Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 36.        SAM Parenteral Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 37.        SAM Topical Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 38.        SAM Others Market Revenue and Forecast to 2028 (US$ Billion)
  • Figure 39.        SAM Branded Generics Market Overview, by Country (2022)
  • Figure 40.        SAM: Branded Generics Market Revenue and Forecasts to 2028, By Country (%)
  • Figure 41.        Argentina: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
  • Figure 42.        Brazil: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
  • Figure 43.        Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
  • Figure 44.        Growth Strategies Done by the Companies in the Market (%)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!